Dr. Mary Edmonds is a small animal clinician practicing veterinary medicine and surgery with over 10 years of clinical experience and a native of Mobile, Alabama. She contributes a perspective on veterinary medicine, applicability of testing and animal welfare as it pertains to clinical trials.
Dr, Edmonds received a Bachelor’s of Science in Biology from the College of Charleston in South Carolina in 2001 with minors in chemistry and psychology. In 2010, she received Doctor of Veterinary Medicine degree from the prestigious Auburn University College of Veterinary Medicine in 2010. While at Auburn University CVM , she received the Whitley Ophthalmology Award and participated in research with alpacas relating to BVDV (Bovine Viral Diarrhea Virus) seroconversion and viral shedding in novel hosts. Dr. Edmonds launched her career in Mobile after graduation focusing on providing medical care and general surgery as an associate veterinarian in general practice. In 2014, she joined Spring Hill Animal Clinic in Mobile, Alabama. Dr. Edmonds then purchased the private practice in 2018 and acts as a co-owner and veterinarian with one other practice partner. She continues to practice as a primary care veterinarian as well as refine surgical technique for high quality, high volume spay and neuter for shelters, rescue groups and the general public. She is a member of the American Veterinary Medical Association and the Mobile Veterinary Medical Association.
Dr. Edmonds participates in primary animal research in the areas of interest to Innovative Medicine Partners and aids in research for various projects under development. She also works closely with Dr. Victoria Hampshire to produce Innovative Medicine Partners’ clinical protocols for animal trials performed by GCMI. Dr. Edmonds will co-author and publish the results and analysis of clinical animal trials.
She serves on the executive management team in the capacity of Chief Animal Research Officer. Dr. Edmonds also serves as a medical advisor to a large private investment group to evaluate multiple medical investing opportunities within the US.